192 related articles for article (PubMed ID: 7997072)
41. Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis.
Fisher A; Brandeis R; Haring R; Eshhar N; Heldman E; Karton Y; Eisenberg O; Meshulam H; Marciano D; Bar-Ner N; Pittel Z
J Physiol Paris; 1998; 92(5-6):337-40. PubMed ID: 9789833
[TBL] [Abstract][Full Text] [Related]
42. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
[TBL] [Abstract][Full Text] [Related]
43. New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
Greig NH; Reale M; Tata AM
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):123-41. PubMed ID: 23597304
[TBL] [Abstract][Full Text] [Related]
44. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.
Davie BJ; Christopoulos A; Scammells PJ
ACS Chem Neurosci; 2013 Jul; 4(7):1026-48. PubMed ID: 23659787
[TBL] [Abstract][Full Text] [Related]
45. Current Advances in Allosteric Modulation of Muscarinic Receptors.
Jakubik J; El-Fakahany EE
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32085536
[TBL] [Abstract][Full Text] [Related]
46. Allosteric modulators targeting CNS muscarinic receptors.
Bock A; Schrage R; Mohr K
Neuropharmacology; 2018 Jul; 136(Pt C):427-437. PubMed ID: 28935216
[TBL] [Abstract][Full Text] [Related]
47. Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes.
Lee NH; el-Fakahany EE
J Pharmacol Exp Ther; 1991 Feb; 256(2):468-79. PubMed ID: 1993991
[TBL] [Abstract][Full Text] [Related]
48. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model.
Puri V; Wang X; Vardigan JD; Kuduk SD; Uslaner JM
Behav Brain Res; 2015; 287():96-9. PubMed ID: 25800972
[TBL] [Abstract][Full Text] [Related]
49. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.
Greenlee W; Clader J; Asberom T; McCombie S; Ford J; Guzik H; Kozlowski J; Li S; Liu C; Lowe D; Vice S; Zhao H; Zhou G; Billard W; Binch H; Crosby R; Duffy R; Lachowicz J; Coffin V; Watkins R; Ruperto V; Strader C; Taylor L; Cox K
Farmaco; 2001 Apr; 56(4):247-50. PubMed ID: 11421251
[TBL] [Abstract][Full Text] [Related]
50. M1 agonists as a potential disease-modifying therapy for Alzheimer's disease.
Caccamo A; Fisher A; LaFerla FM
Curr Alzheimer Res; 2009 Apr; 6(2):112-7. PubMed ID: 19355845
[TBL] [Abstract][Full Text] [Related]
51. Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease.
Chintamaneni PK; Krishnamurthy PT; Rao PV; Pindiprolu SS
Med Hypotheses; 2017 Apr; 101():17-22. PubMed ID: 28351483
[TBL] [Abstract][Full Text] [Related]
52. Outline of therapeutic interventions with muscarinic receptor-mediated transmission.
Jakubík J; Šantrůčková E; Randáková A; Janíčková H; Zimčík P; Rudajev V; Michal P; El-Fakahany EE; Doležal V
Physiol Res; 2014; 63(Suppl 1):S177-89. PubMed ID: 24564657
[TBL] [Abstract][Full Text] [Related]
53. Progress in medicinal chemistry of novel selective muscarinic agonists.
Fisher A; Karton Y; Heldman E; Gurwitz D; Haring R; Meshulam H; Brandeis R; Pittel Z; Segall Y; Marciano D
Drug Des Discov; 1993; 9(3-4):221-35. PubMed ID: 8400004
[TBL] [Abstract][Full Text] [Related]
54. Opportunities and challenges for the development of M
Nguyen HTM; van der Westhuizen ET; Langmead CJ; Tobin AB; Sexton PM; Christopoulos A; Valant C
Br J Pharmacol; 2024 Jul; 181(14):2114-2142. PubMed ID: 36355830
[TBL] [Abstract][Full Text] [Related]
55. Cholinergic agonists and the treatment of Alzheimer's disease.
Messer WS
Curr Top Med Chem; 2002 Apr; 2(4):353-8. PubMed ID: 11966459
[TBL] [Abstract][Full Text] [Related]
56. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
Cembala TM; Sherwin JD; Tidmarsh MD; Appadu BL; Lambert DG
Br J Pharmacol; 1998 Nov; 125(5):1088-94. PubMed ID: 9846649
[TBL] [Abstract][Full Text] [Related]
57. Oxotremorine-M potentiates NMDA receptors by muscarinic receptor dependent and independent mechanisms.
Zwart R; Reed H; Sher E
Biochem Biophys Res Commun; 2018 Jan; 495(1):481-486. PubMed ID: 29127015
[TBL] [Abstract][Full Text] [Related]
58. Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors.
Michal P; Lysíková M; El-Fakahany EE; Tucek S
Eur J Pharmacol; 1999 Jul; 376(1-2):119-25. PubMed ID: 10440097
[TBL] [Abstract][Full Text] [Related]
59. Muscarinic acetylcholine receptors: novel opportunities for drug development.
Kruse AC; Kobilka BK; Gautam D; Sexton PM; Christopoulos A; Wess J
Nat Rev Drug Discov; 2014 Jul; 13(7):549-60. PubMed ID: 24903776
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
Roffel AF; Davids JH; Elzinga CR; Wolf D; Zaagsma J; Kilbinger H
Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
